UBS Group started coverage on shares of Kyverna Therapeutics (NASDAQ:KYTX – Free Report) in a research report sent to investors on Thursday morning, Marketbeat.com reports. The firm issued a buy rating and a $13.00 target price on the stock.
Other equities analysts have also issued reports about the stock. JPMorgan Chase & Co. dropped their price target on shares of Kyverna Therapeutics from $39.00 to $33.00 and set an overweight rating on the stock in a research note on Wednesday, July 31st. RODMAN&RENSHAW raised Kyverna Therapeutics to a strong-buy rating in a report on Wednesday. Rodman & Renshaw began coverage on Kyverna Therapeutics in a report on Wednesday. They issued a buy rating and a $16.00 price objective for the company. Finally, HC Wainwright reissued a neutral rating and issued a $7.00 price objective on shares of Kyverna Therapeutics in a report on Thursday, September 19th. One investment analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Kyverna Therapeutics has an average rating of Buy and an average price target of $28.71.
View Our Latest Stock Analysis on KYTX
Kyverna Therapeutics Stock Performance
Kyverna Therapeutics (NASDAQ:KYTX – Get Free Report) last announced its quarterly earnings results on Monday, August 12th. The company reported ($0.67) EPS for the quarter, beating the consensus estimate of ($0.70) by $0.03. Research analysts forecast that Kyverna Therapeutics will post -3.38 EPS for the current fiscal year.
Institutional Investors Weigh In On Kyverna Therapeutics
Several hedge funds have recently modified their holdings of the stock. Teachers Retirement System of The State of Kentucky lifted its holdings in Kyverna Therapeutics by 69.7% in the second quarter. Teachers Retirement System of The State of Kentucky now owns 21,410 shares of the company’s stock valued at $161,000 after acquiring an additional 8,796 shares during the period. Novo Holdings A S lifted its holdings in Kyverna Therapeutics by 150.0% in the second quarter. Novo Holdings A S now owns 1,750,000 shares of the company’s stock valued at $13,125,000 after acquiring an additional 1,050,000 shares during the period. The Manufacturers Life Insurance Company lifted its holdings in Kyverna Therapeutics by 32.6% in the second quarter. The Manufacturers Life Insurance Company now owns 37,794 shares of the company’s stock valued at $283,000 after acquiring an additional 9,300 shares during the period. Millennium Management LLC lifted its holdings in Kyverna Therapeutics by 32.8% in the second quarter. Millennium Management LLC now owns 923,082 shares of the company’s stock valued at $6,923,000 after acquiring an additional 227,988 shares during the period. Finally, MBB Public Markets I LLC acquired a new stake in Kyverna Therapeutics in the second quarter valued at $3,076,000. 18.08% of the stock is owned by institutional investors and hedge funds.
Kyverna Therapeutics Company Profile
Kyverna Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.
Read More
- Five stocks we like better than Kyverna Therapeutics
- What is the Nikkei 225 index?
- 3 Micro-Caps Set for Major Moves: Balancing Risk and Opportunity
- Stock Splits, Do They Really Impact Investors?
- Autodesk Named a “Top Pick” by Morgan Stanley—Is It Time to Buy?
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- 4 Quirky ETFs With Big Potential for Impressive Gains
Receive News & Ratings for Kyverna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kyverna Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.